Living Cell Technologies Limited (LVCLF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 178.44 Thousand AUD | -60.33% |
| 2023 | 449.85 Thousand AUD | 88.02% |
| 2022 | 239.25 Thousand AUD | -9.74% |
| 2021 | 265.08 Thousand AUD | -48.3% |
| 2020 | 512.72 Thousand AUD | -68.37% |
| 2019 | 1.62 Million AUD | 242.39% |
| 2018 | 473.47 Thousand AUD | -59.74% |
| 2017 | 1.17 Million AUD | 84.97% |
| 2016 | 635.79 Thousand AUD | 88.3% |
| 2015 | 337.65 Thousand AUD | -72.62% |
| 2014 | 1.23 Million AUD | 27.64% |
| 2013 | 966 Thousand AUD | -17.44% |
| 2012 | 1.17 Million AUD | 64.47% |
| 2011 | 711.39 Thousand AUD | 1.09% |
| 2010 | 703.74 Thousand AUD | -27.65% |
| 2009 | 972.63 Thousand AUD | 36.19% |
| 2008 | 714.19 Thousand AUD | -70.44% |
| 2007 | 2.41 Million AUD | -3.91% |
| 2006 | 2.51 Million AUD | 210.76% |
| 2005 | 809.16 Thousand AUD | -69.29% |
| 2004 | 2.63 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 178.44 Thousand AUD | -60.33% |
| 2024 Q1 | 140.16 Thousand AUD | -41.42% |
| 2024 Q3 | 178.44 Thousand AUD | 27.32% |
| 2024 Q4 | 178.44 Thousand AUD | 0.0% |
| 2024 Q2 | 140.16 Thousand AUD | 0.0% |
| 2023 FY | 449.85 Thousand AUD | 88.02% |
| 2023 Q4 | 239.25 Thousand AUD | -46.81% |
| 2023 Q1 | 382.76 Thousand AUD | 59.98% |
| 2023 Q2 | 382.76 Thousand AUD | 0.0% |
| 2023 Q3 | 449.85 Thousand AUD | 17.53% |
| 2022 FY | 239.25 Thousand AUD | -9.74% |
| 2022 Q4 | 239.25 Thousand AUD | 0.0% |
| 2022 Q3 | 239.25 Thousand AUD | -36.66% |
| 2022 Q2 | 377.73 Thousand AUD | 0.0% |
| 2022 Q1 | 377.73 Thousand AUD | 42.5% |
| 2021 Q3 | 265.08 Thousand AUD | -40.02% |
| 2021 Q4 | 265.08 Thousand AUD | 0.0% |
| 2021 Q1 | 441.93 Thousand AUD | -13.81% |
| 2021 Q2 | 441.93 Thousand AUD | 0.0% |
| 2021 FY | 265.08 Thousand AUD | -48.3% |
| 2020 Q2 | 644.55 Thousand AUD | 0.0% |
| 2020 FY | 512.72 Thousand AUD | -68.37% |
| 2020 Q3 | 512.72 Thousand AUD | -20.45% |
| 2020 Q1 | 644.55 Thousand AUD | -60.24% |
| 2020 Q4 | 512.72 Thousand AUD | 0.0% |
| 2019 Q1 | 350.69 Thousand AUD | -25.93% |
| 2019 FY | 1.62 Million AUD | 242.39% |
| 2019 Q2 | 350.69 Thousand AUD | 0.0% |
| 2019 Q3 | 1.62 Million AUD | 362.27% |
| 2019 Q4 | 1.62 Million AUD | 0.0% |
| 2018 Q4 | 473.47 Thousand AUD | 0.0% |
| 2018 Q3 | 473.47 Thousand AUD | 34.83% |
| 2018 Q2 | 351.16 Thousand AUD | 0.0% |
| 2018 Q1 | 351.16 Thousand AUD | -70.14% |
| 2018 FY | 473.47 Thousand AUD | -59.74% |
| 2017 FY | 1.17 Million AUD | 84.97% |
| 2017 Q2 | 431.72 Thousand AUD | 0.0% |
| 2017 Q3 | 1.17 Million AUD | 172.4% |
| 2017 Q4 | 1.17 Million AUD | 0.0% |
| 2017 Q1 | 431.72 Thousand AUD | -32.1% |
| 2016 Q1 | 898.73 Thousand AUD | 166.17% |
| 2016 Q3 | 635.79 Thousand AUD | -29.26% |
| 2016 FY | 635.79 Thousand AUD | 88.3% |
| 2016 Q4 | 635.79 Thousand AUD | 0.0% |
| 2016 Q2 | 898.73 Thousand AUD | 0.0% |
| 2015 Q2 | 417.29 Thousand AUD | 0.0% |
| 2015 FY | 337.65 Thousand AUD | -72.62% |
| 2015 Q4 | 337.65 Thousand AUD | 0.0% |
| 2015 Q3 | 337.65 Thousand AUD | -19.08% |
| 2015 Q1 | 417.29 Thousand AUD | -66.16% |
| 2014 Q1 | 1.85 Million AUD | 91.72% |
| 2014 FY | 1.23 Million AUD | 27.64% |
| 2014 Q4 | 1.23 Million AUD | 0.0% |
| 2014 Q3 | 1.23 Million AUD | -33.42% |
| 2014 Q2 | 1.85 Million AUD | 0.0% |
| 2013 FY | 966 Thousand AUD | -17.44% |
| 2013 Q4 | 966 Thousand AUD | -0.03% |
| 2013 Q3 | 966.31 Thousand AUD | 0.0% |
| 2012 FY | 1.17 Million AUD | 64.47% |
| 2012 Q4 | 1.17 Million AUD | 0.0% |
| 2011 FY | 711.39 Thousand AUD | 1.09% |
| 2011 Q4 | 711.39 Thousand AUD | 0.0% |
| 2010 FY | 703.74 Thousand AUD | -27.65% |
| 2010 Q4 | 703.74 Thousand AUD | 0.0% |
| 2009 Q4 | 972.63 Thousand AUD | 0.0% |
| 2009 FY | 972.63 Thousand AUD | 36.19% |
| 2008 Q4 | 714.19 Thousand AUD | 0.0% |
| 2008 FY | 714.19 Thousand AUD | -70.44% |
| 2007 Q4 | 2.41 Million AUD | 0.0% |
| 2007 FY | 2.41 Million AUD | -3.91% |
| 2006 Q4 | 2.51 Million AUD | 0.0% |
| 2006 FY | 2.51 Million AUD | 210.76% |
| 2005 FY | 809.16 Thousand AUD | -69.29% |
| 2005 Q4 | 809.16 Thousand AUD | 0.0% |
| 2004 FY | 2.63 Million AUD | 0.0% |
| 2004 Q4 | 2.63 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ContraFect Corporation | 32.53 Million USD | 99.451% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.665% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 98.138% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 57.67% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.643% |
| Intellipharmaceutics International Inc. | 12 Million USD | 98.514% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.754% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.698% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 95.367% |
| Marizyme, Inc. | 26.67 Million USD | 99.331% |
| Genus plc | 485 Million USD | 99.963% |
| Pharming Group N.V. | 244.07 Million USD | 99.927% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 91.123% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 92.908% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 95.304% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 95.338% |
| IMV Inc. | 37.93 Million USD | 99.53% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 98.485% |
| ONE Bio Corp. | 27.49 Million USD | 99.351% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.769% |
| Neon Bloom, Inc. | 1.22 Million USD | 85.447% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 96.532% |
| Biomind Labs Inc. | 1.49 Million USD | 88.092% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.85% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 99.03% |
| Skye Bioscience, Inc. | 14.07 Million USD | 98.732% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 87.555% |
| Mesoblast Limited | 188.44 Million USD | 99.905% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -25.584% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 98.115% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 11.271% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 96.894% |
| GB Sciences, Inc. | 5.41 Million USD | 96.706% |
| MultiCell Technologies, Inc. | 1617.67 USD | -10931.174% |
| Alpha Cognition Inc. | 7.16 Million USD | 97.509% |
| HST Global, Inc. | 593.59 Thousand USD | 69.938% |
| CSL Limited | 18.62 Billion USD | 99.999% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 2.51 Million USD | 92.892% |
| Halberd Corporation | 728.71 Thousand USD | 75.512% |
| Enzolytics Inc. | 365.26 Million USD | 99.951% |
| Resverlogix Corp. | 67.39 Million USD | 99.735% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 78.724% |
| argenx SE | 444.95 Million USD | 99.96% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 89.589% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.785% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 95.131% |
| Bioxytran, Inc. | 3.24 Million USD | 94.508% |
| Zenith Capital Corp. | 27.56 Thousand USD | -547.278% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 95.221% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 73.79% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 93.419% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.987% |
| Kadimastem Ltd | 3.5 Million USD | 94.909% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -166.623% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 98.026% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.645% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 96.946% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 90.993% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | 83.465% |
| EV Biologics, Inc. | 2.11 Million USD | 91.563% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 61.599% |
| Q BioMed Inc. | 8.13 Million USD | 97.806% |
| LadRx Corporation | 2.2 Million USD | 91.891% |
| Cell Source, Inc. | 15.8 Million USD | 98.871% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -299.248% |
| Regen BioPharma, Inc. | 5.45 Million USD | 96.73% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.762% |
| Itoco Inc. | 1.65 Million USD | 89.206% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 91.302% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 85.828% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 99.279% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 97.05% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 98.501% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | 95.532% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 25.227% |
| NovAccess Global Inc. | 7.86 Million USD | 97.73% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -326.919% |
| BioStem Technologies, Inc. | 15.9 Million USD | 98.878% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 88.608% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -550.487% |
| Qrons Inc. | 1.48 Million USD | 88.013% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 98.384% |
| SYBLEU INC | 681.41 Thousand USD | 73.812% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 77.937% |
| Rebus Holdings, Inc. | 5.24 Million USD | 96.596% |
| Regen BioPharma, Inc. | 5.45 Million USD | 96.73% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 97.076% |
| Affymax, Inc. | 8.87 Million USD | 97.988% |
| Mobile Lads Corp. | 1.31 Million USD | 86.414% |
| International Stem Cell Corporation | 5.27 Million USD | 96.618% |
| CytoDyn Inc. | 127.89 Million USD | 99.86% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 71.485% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 96.135% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.565% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 99.199% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 91.189% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 96.742% |
| Neutra Corp. | 973.52 Thousand USD | 81.67% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.385% |
| PureTech Health plc | 125.58 Million USD | 99.858% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 95.25% |
| IXICO plc | 1.9 Million USD | 90.609% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 99.131% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.827% |
| CSL Limited | 18.62 Billion USD | 99.999% |
| Cellectis S.A. | 249.36 Million USD | 99.928% |